PharmaCyte net loss widens to $19.42 million in FY26; revenue remains no revenue
PMCB•Clinical hold update
The company continues work to lift the FDA clinical hold on its IND for a planned locally advanced pancreatic cancer trial using Cell-in-a-Box encapsulated live cells.
FY26 results show wider loss and no revenue
- PharmaCyte Biotech posted a net loss of USD 19.42 million for fiscal 2026, swinging from net income of USD 30.66 million a year earlier.
- Other income fell to a net expense of USD 12.57 million from net income of USD 35.03 million, driven by fair-value losses on QCLS and warrant positions.
- Operating expenses climbed 56.5% to USD 6.85 million, including a USD 1.55 million impairment charge; R&D spending edged down to USD 391,301.
- Cash and cash equivalents rose to USD 18.6 million, while working capital increased to USD 36.6 million.
